Raymond James Trust’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $399K | Buy |
2,572
+88
| +4% | +$13.1K | 0.01% | 891 |
|
|
2024
Q2 | $340K | Sell |
2,484
-272
| -10% | -$37.2K | 0.01% | 911 |
|
|
2024
Q1 | $367K | Buy |
2,756
+283
| +11% | +$36.7K | 0.01% | 868 |
|
|
2023
Q4 | $341K | Buy |
2,473
+775
| +46% | +$102K | 0.01% | 861 |
|
|
2023
Q3 | $207K | Buy |
1,698
+103
| +6% | +$13.7K | 0.01% | 1071 |
|
|
2023
Q2 | $225K | Sell |
1,595
-50
| -3% | -$6.89K | 0.01% | 1053 |
|
|
2023
Q1 | $233K | Sell |
1,645
-91
| -5% | -$13K | 0.01% | 996 |
|
|
2022
Q4 | $272K | Buy |
+1,736
| New | +$249K | 0.01% | 879 |
|
|
2022
Q3 | – | Sell |
-2,256
| Closed | -$300K | – | 1082 |
|
|
2022
Q2 | $300K | Buy |
2,256
+156
| +7% | +$21.3K | 0.01% | 808 |
|
|
2022
Q1 | $288K | Sell |
2,100
-97
| -4% | -$13.5K | 0.01% | 902 |
|
|
2021
Q4 | $380K | Sell |
2,197
-1,090
| -33% | -$166K | 0.01% | 771 |
|
|
2021
Q3 | $477K | Sell |
3,287
-413
| -11% | -$60.4K | 0.02% | 633 |
|
|
2021
Q2 | $488K | Sell |
3,700
-120
| -3% | -$15.7K | 0.02% | 616 |
|
|
2021
Q1 | $490K | Buy |
3,820
+734
| +24% | +$90.4K | 0.02% | 599 |
|
|
2020
Q4 | $368K | Sell |
3,086
-431
| -12% | -$52.5K | 0.01% | 669 |
|
|
2020
Q3 | $403K | Sell |
3,517
-79
| -2% | -$9.33K | 0.02% | 564 |
|
|
2020
Q2 | $410K | Sell |
3,596
-149
| -4% | -$15.8K | 0.02% | 531 |
|
|
2020
Q1 | $301K | Buy |
3,745
+780
| +26% | +$80.8K | 0.02% | 543 |
|
|
2019
Q4 | $317K | Sell |
2,965
-662
| -18% | -$69K | 0.02% | 662 |
|
|
2019
Q3 | $388K | Sell |
3,627
-130
| -3% | -$13.3K | 0.02% | 549 |
|
|
2019
Q2 | $383K | Buy |
3,757
+1,236
| +49% | +$119K | 0.02% | 532 |
|
|
2019
Q1 | $227K | Buy |
+2,521
| New | +$218K | 0.01% | 720 |
|
|
2016
Q3 | – | Sell |
-7,577
| Closed | -$617K | – | 687 |
|
|
2016
Q2 | $617K | Buy |
7,577
+253
| +3% | +$19.3K | 0.05% | 294 |
|
|
2016
Q1 | $524K | Sell |
7,324
-1,887
| -20% | -$127K | 0.05% | 316 |
|
|
2015
Q4 | $655K | Sell |
9,211
-256
| -3% | -$17.2K | 0.06% | 284 |
|
|
2015
Q3 | $582K | Buy |
9,467
+745
| +9% | +$52.1K | 0.07% | 269 |
|
|
2015
Q2 | $633K | Sell |
8,722
-608
| -7% | -$44.9K | 0.07% | 264 |
|
|
2015
Q1 | $717K | Buy |
9,330
+750
| +9% | +$53.7K | 0.08% | 250 |
|
|
2014
Q4 | $576K | Buy |
8,580
+249
| +3% | +$15.7K | 0.06% | 289 |
|
|
2014
Q3 | $506K | Buy |
8,331
+1,506
| +22% | +$92.8K | 0.06% | 299 |
|
|
2014
Q2 | $401K | Buy |
6,825
+2,748
| +67% | +$161K | 0.05% | 355 |
|
|
2014
Q1 | $236K | Buy |
+4,077
| New | +$219K | 0.03% | 472 |
|
Other funds holding DGX
DSA
Raymond James Trust's DGX Position: Q3 2024 in Review
Raymond James Trust increased its Quest Diagnostics (DGX) stake by 3.5% in Q3 2024, buying an estimated $13.1K and bringing the position to 2,572 shares worth $399K. The position accounts for 0.01% of the portfolio, ranked #891.
Raymond James Trust first reported a position in DGX in Q1 2014 and has held it in 32 quarters since. The position peaked at $717K in Q1 2015. 846 funds tracked by Wall St. Rank hold DGX as of Q3 2024.
- Raymond James Trust held 2,572 shares of Quest Diagnostics worth $399K as of Q3 2024.
- Raymond James Trust bought 88 Quest Diagnostics shares in Q3 2024, an estimated $13.1K.
- Quest Diagnostics made up 0.01% of Raymond James Trust's portfolio in Q3 2024, its #891 holding.
- Raymond James Trust first reported a position in Quest Diagnostics in Q1 2014 and has held it in 32 quarters since.
- Raymond James Trust's Quest Diagnostics position peaked at $717K in Q1 2015.
- 846 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2024.
Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.